Semaglutide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of Semaglutide is 7 days. This means dosing once weekly (injection) or daily (oral) is typical to maintain stable levels. The half-life directly affects how long Semaglutide remains active and influences optimal injection timing.
What Is the Half-Life of Semaglutide?
The half-life of Semaglutide is 7 days. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer Semaglutide to maintain therapeutic blood levels.
What Does Semaglutide's Half-Life Mean for Dosing?
With a half-life of 7 days, Semaglutide requires dosing once weekly (injection) or daily (oral) to maintain stable levels. The standard dosage of 0.25-2.4 mg weekly (injection) or 3-14 mg daily (oral) via subcutaneous injection or oral accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, Semaglutide reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For Semaglutide, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject Semaglutide?
Optimal timing depends on your research goals. A half-life of 7 days means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (once weekly (injection) or daily (oral)) for more stable levels throughout the day.
How Does Semaglutide's Half-Life Compare to Similar Peptides?
Semaglutide is a GLP-1 receptor agonist incretin mimetic. Its half-life of 7 days positions it with a longer duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your Semaglutide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Semaglutide.
Open Calculator →Bottom Line: Semaglutide Half-Life and Dosing
Semaglutide has a half-life of 7 days, supporting the standard protocol of 0.25-2.4 mg weekly (injection) or 3-14 mg daily (oral) dosed once weekly (injection) or daily (oral) over ongoing, titrated over 4-5 weeks.
Read our Semaglutide dosage guide for complete protocol details.
Complete Guide
Semaglutide : Benefits, Dosage, Side Effects & Research
Related Reading
- Semaglutide Dosage Guide
- Semaglutide Benefits
- Semaglutide Side Effects
- Semaglutide Stacking Guide
- Semaglutide Cycle Guide
- Semaglutide Research
Research-Grade Sourcing
If you're going to research Semaglutide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Semaglutide?
Semaglutide (Semaglutide (GLP-1 receptor agonist)) is a GLP-1 receptor agonist incretin mimetic. Synthetic GLP-1 analog developed by Novo Nordisk with amino acid modifications for extended half-life. It is researched for weight loss (16-22.5%), glycemic control, cardiovascular event reduction, appetite suppression.
What is the recommended Semaglutide dosage?
Common dosages: 0.25-2.4 mg weekly (injection) or 3-14 mg daily (oral) administered once weekly (injection) or daily (oral) via subcutaneous injection or oral. Cycle length: ongoing, titrated over 4-5 weeks. Half-life: 7 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Semaglutide?
Nausea, vomiting, diarrhea (20-40% incidence, decreasing over 4-8 weeks). Thyroid C-cell tumor risk in rodents (human relevance unclear). Rare pancreatitis and diabetic retinopathy worsening.
Is Semaglutide safe?
Semaglutide has shown a preliminary safety profile in research. FDA-approved for type 2 diabetes (Ozempic), weight management (Wegovy), and chronic kidney disease. Prescription medication. All research should follow appropriate safety protocols.